Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenograftsCHECKLEY, David; TESSIER, Jean J. L; WEDGE, Stephen R et al.Magnetic resonance imaging. 2003, Vol 21, Num 5, pp 475-482, issn 0730-725X, 8 p.Article

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationWEDGE, Stephen R; OGILVIE, Donald J; GRAHAM, George A et al.Cancer research (Baltimore). 2002, Vol 62, Num 16, pp 4645-4655, issn 0008-5472Article

ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapyWAKELING, Alan E; GUY, Simon P; WOODBURN, Jim R et al.Cancer research (Baltimore). 2002, Vol 62, Num 20, pp 5749-5754, issn 0008-5472, 6 p.Article

Studies leading to the identification of ZD1839 (Iressa⁾ : An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancerBARKER, Andrew J; GIBSON, Keith H; HENTHORN, Lianne et al.Bioorganic & medicinal chemistry letters (Print). 2001, Vol 11, Num 14, pp 1911-1914, issn 0960-894XArticle